Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
Vivos Inc. submitted an Early Feasibility Investigational Device Exemption (IDE) application to the FDA for its RadioGel precision radionuclide therapy. The submission includes strengthened technical data, preclinical evidence, and safety data from over 200 veterinary patients using the related IsoPet product.
Key figures
- Drug Name
- RadioGel
- Veterinary patients
- over 200
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.